Cancer is one of the diseases that concerns the most in human and veterinary medicine taking an important role at scientific research. In 2012, more than 14 million people died of different types of cancer and it is expected that this number increases up to 20 million in 2025. Cancer is responsible for about 50% of deaths of dogs older than 10 years and mammary neoplasias are the most common, corresponding to 52% of the cases. Veterinary oncology it is still fairly timid when compared to human oncology research, however therapeutic target research focused on veterinary cancer diagnosis and prognosis has increased on the past few years. Immunotherapy is one of those therapeutic strategies capable of inducing the immune system to combat cancer cells. Recent immunotherapy approachs based on neoantigens aim to increase antigenicity of imunotherapeutic vaccines to induce the immune response. This propose focuses on detection of neoepitopes exhibition by major histocompatibility complex 1 (MHC1) in canine cancer cells. The project aims to develop and validate a canine MHC epitope prediction model to indentify potential immunotherapeuctic targets in cancer cells. To achieve the aim of the propose, we divided the project in two diferent studies; Study 1, construction of a canine MHC-I prediction model based on MHC-I peptidomic data, and the Study 2, the characterization and validation of the MHC predicting model using a mutation profile based on exome and transcriptome analysis. The development of this technology has a huge impact on veterinary medicine in general and canine immunology in particular since no prediction model has yet been described, focusing on this kind of research. Besides, this technology will improve the way of the immunotherapy against cancer in veterinary medicine, expanding new T Cell-dependent therapies crossing from human to veterinary medicine.
News published in Agência FAPESP Newsletter about the scholarship: